Novo Nordisk shares fell 7% after the company confirmed semaglutide patent expirations starting in 2032 and reported underwhelming Phase 3 trial results for its experimental drug, CagriSema.
Shares plunged over 7% as new long-term targets failed to reassure investors regarding patent expirations and competitive pressures in the weight-loss drug market.
Mentioned as a key competitor holding 61% of the obesity drug market with superior trial results for tirzepatide compared to Novo's CagriSema.
Novo Nordisk shares dropped over 7% to $39.82 as investors reacted to looming patent expirations for its blockbuster drug semaglutide. Despite ambitious long-term growth targets, the company faces intense pressure from Eli Lilly, which currently commands 61% of the obesity drug market.
Investors were concerned by the confirmation of patent expirations for semaglutide starting in 2032 and disappointing trial results for the experimental drug CagriSema, which failed to outperform Eli Lilly's tirzepatide.